The Pharmaceutical Journal
Vol 277 No 7429 p659
2 December 2006

This article
Reprint   Photocopy

  Acrobat Reader

News summary

New CML treatment available

A new treatment for chronic myeloid leukaemia (CML) has been launched by Bristol-Myers Squibb.

Dasatinib, marketed as Sprycel, is indicated for the treatment of adults with chronic, accelerated or blast phase CML, with resistance or intolerance to prior therapy. It also has an indication for the treatment of adults with Philadelphia chromosome positive acute lymphoblastic leukaemia and lymphoid blast CML with resistance or intolerance to prior therapy.

Dasatinib is a protein kinase inhibitor that binds to the inactive and active conformations of the BCR-ABL kinase. It inhibits the activity of the BCR-ABL kinase and the activity of the SRC family kinases and a number of other oncogenic kinases.


Notice-board p663